secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001551152-26-000011
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie records $744M IPR&D expense in Q1; cuts adjusted EPS guidance by $0.41
-----------------------------------------------------------------------------

- Q1 2026 includes $744M pre-tax acquired IPR&D and milestones expense, reducing EPS by $0.41.
- Updated Q1 adjusted EPS guidance: $2.56-$2.60 (from $2.97-$3.01, excluding Q1 IPR&D).
- Full-year 2026 adjusted EPS guidance lowered to $13.96-$14.16 (from $14.37-$14.57).
- Company states future IPR&D milestones cannot be reliably forecasted; guidance excludes them beyond Q1.
- Adjusted diluted EPS guidance now includes impact of Q1 expense; prior range excluded it.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000011/0001551152-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115226000011/abbv-20260403.htm
  HTML page:      https://secwatch.observer/filing/0001551152-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer